Ruxolitinib for Premalignant Breast Disease

Clinical trial NCT02928978 · COMPLETED

Trial details

NCT number: NCT02928978
Sponsor: Julie Nangia
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Ductal Carcinoma In Situ Atypical Lobular Hyperplasia Atypical Ductal Hyperplasia Lobular Carcinoma In Situ

Start date: 2018-05-13
Primary completion: 2024-08-29
Enrollment: 84

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.